Article
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Aug 2005
Schilder Russell J, Sill Michael W, Chen Xiaowei, Darcy Kathleen M, Decesare Steven L, Lewandowski George, Lee Roger B, Arciero Cletus A, Wu Hong, Godwin Andrew K
Abstract excerpt
PURPOSE: This phase II trial assessed the activity and tolerability of a daily oral dose of 500 mg gefitinib (ZD1839, Iressa) in patients with recurrent or persistent epithelial ovarian or primary peritoneal carcinoma, and explored the clinical value of determining the status of the epidermal growth factor receptor (EGFR). EXPERIMENTAL DESIGN: Primary measure of efficacy was progression-free survival at 6 months....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.